Weight-loss experts predict 5 major treatment changes likely to emerge in 2026

Big shifts are expected to keep reshaping the weight-loss world in 2026, driven by ongoing research into GLP-1 medications and other emerging approaches. Several weight-loss specialists predict a handful of changes that could stand out most in the year ahead.

1) A move toward whole-body treatment, not just weight loss

Experts believe GLP-1 drugs will increasingly be viewed as therapies that affect multiple body systems, rather than being seen only as “weight-loss injections.” The goal, they say, is likely to expand beyond reducing body weight or BMI to lowering overall cardiometabolic risk. That includes improving markers and outcomes linked to the heart, liver, kidneys, and blood vessels, with studies increasingly pointing to broader protective effects.

At the same time, next-generation medications and combinations are expected to gain attention. These may include newer GLP-1 and GIP options and other hormone-based combinations that could produce greater weight loss, better long-term maintenance, and improved tolerability for some patients. There’s also optimism that new government and manufacturer agreements could make these medications easier to access and more affordable for people who need them.

2) More convenient ways to take the medication

Currently, many GLP-1 treatments are taken as a once-weekly injection. Looking ahead, specialists anticipate more user-friendly dosing options. This could mean more pills instead of injections, including advances in oral GLP-1 formulations, and possibly longer-lasting delivery systems such as implants designed to provide medication over several months.

3) Growth in less invasive weight-loss procedures

Alongside medication advances, experts expect continued momentum in minimally invasive and incision-free procedures. Techniques done through endoscopy, such as procedures that reduce stomach capacity from the inside or target part of the small intestine to improve blood-sugar handling, may become more widely available and longer-lasting. The appeal is that these options can offer meaningful metabolic and weight benefits with quicker recovery times and lower risk than traditional surgery.

That said, bariatric surgeons still emphasize that weight-loss surgery remains the most effective option overall for severe obesity, especially in terms of the amount of weight lost and how long results tend to last.

4) More younger patients using GLP-1 treatments

Because some GLP-1 medications are already approved for adolescents, experts say pediatric use is no longer theoretical. In 2026, they expect additional weight-loss drug options could become available for younger age groups, further expanding who can be treated with medication-based approaches.

5) High-tech, personalized treatment plans

With AI becoming more common in healthcare, specialists predict more technology-driven personalization in obesity treatment. Instead of relying on broad categories and a “try this, then try that” approach, clinicians may increasingly use tools that help identify different patterns or drivers of weight gain, such as appetite regulation issues, emotional eating tendencies, or slower metabolic profiles. The expectation is that more individualized testing and targeted plans will become a bigger focus, since obesity can develop for different reasons in different people—and treatment may need to match the cause.